A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial.
The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of
pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard
of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory
infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory
pathogens) morbidity and mortality in a high-risk cohort of adults with established
atherosclerotic cardiovascular disease (ASCVD).